Form D · Biotechnology
Gladius Pharmaceuticals Corp
Wilmington, DE · CIK 0001646819
Offering snapshot reported Nov 28, 2018 · SEC filing
- Reported sold
- $3.02M Offering amount: $3.02M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 14, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 28, 2018 | Initial | $3,022,400 | No comparison | 5 | SEC filing |
| Jun 30, 2015 | Initial | $727,840 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-326665
The offering amount is based on the exchange rate of C$1 to US$0.7556 on November 14, 2018.
Source: Form D, filed Nov 28, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Atkin | Executive |
| Nathalie Chauret | Director |
| Jens Eckstein | Director |
| Daniel Hetu | Director |
| Larry Sutton | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2711 Centerville Road, Suite 400 County Newcastle
Wilmington, DE, 19808
Wilmington, DE, 19808